

## InMed Pharmaceuticals to Present at the 2017 BIO CEO & Investor Conference

CSE: IN

OTCQB: IMLFF

VANCOUVER, Feb. 9, 2017 /CNW/ - **InMed Pharmaceuticals, Inc.** ("InMed") (CSE: IN; OTCQB: IMLFF), announced today that **Eric A. Adams, Chief Executive Officer**, will provide a corporate overview and business update at the 2017 BIO-CEO & Investor Conference, being held on February 13th-14th, 2017 at the Waldorf Astoria, New York City.



### BIO CEO & Investor Conference - InMed Presentation Details

Date: Tuesday, February 14th

Time: 2:30 Eastern Time

Location: The Waldorf Astoria, New York, New York

Room: Park South

### About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. The **19<sup>th</sup> Annual BIO CEO & Investor Conference** is one of the largest independent investor conferences focused on established and emerging publicly traded and select private biotech companies. Each year the conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. BIO also produces the **BIO International Convention**, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

### About InMed

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary in silico drug/disease targeting platform, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit [www.inmedpharma.com](http://www.inmedpharma.com)

### Forward Looking Statements

*This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the*

*forward-looking statements. Forward-looking information in this news release includes statements about the use of net proceeds from the private placement and the expected fundamental value drivers of the company. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Known risk factors include, among others: InMed may not use net proceeds received from the private placement as currently contemplated and InMed's proprietary platform technology, product pipeline and accelerated development pathway may not return their expected level of value.*

*A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed's continuous disclosure filings with Canadian securities regulatory authorities at [www.sedar.com](http://www.sedar.com). All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.*

**NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.**

SOURCE InMed Pharmaceuticals Inc.

To view this news release in HTML formatting, please use the following URL:  
<http://www.newswire.ca/en/releases/archive/February2017/09/c2972.html>

%SEDAR: 00005782E

**For further information:** InMed Pharmaceuticals Inc., Chris Bogart, SVP, Investor Relations and Corporate Strategy, T: 604.669.7207, E: [chris@inmedpharma.com](mailto:chris@inmedpharma.com)

CO: InMed Pharmaceuticals Inc.

CNW 14:20e 09-FEB-17